Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.36 |
| ▸ | LIMK2 | P53671 | 2/20 | 0.36 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596284 | 0.83 | PDE10A (0.62) | PDE10ATNK2 | |
| SCHEMBL23235670 | 0.76 | ALDH1A1 (0.43) | PDE10AALDH1A1SMN1; SMN2TNK2TRPV1 | |
| SCHEMBL9988855 | 0.74 | PDE10A (0.70) | PDE10A | |
| SCHEMBL27934371 | 0.74 | PDE10A (0.84) | PDE10A | |
| SCHEMBL2596306 | 0.73 | PDE10A (0.40) | PDE10ATRPV1 | |
| SCHEMBL6649430 | 0.70 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LIMK1LIMK2TRPV1 | |
| SCHEMBL27911596 | 0.70 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2LIMK1LIMK2TNK2 | |
| SCHEMBL14655987 | 0.70 | KDM4E (0.53) | ALDH1A1SMN1; SMN2TRPV1 | |
| SCHEMBL2595677 | 0.70 | SIGMAR1 (0.39) | ALDH1A1 | |
| SCHEMBL10317879 | 0.69 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213572-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | PDE10A 1/4885ALDH1A1 526/4885SMN1; SMN2 1563/4885 |
| US-20110306587-A1 | UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS | PDE10A, PDE2A, PDE3A | PDE10A 1/4885ALDH1A1 526/4885SMN1; SMN2 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.